Loading…
Results show enhanced efficacy when combined with tirzepatide.
Skye Bioscience, Inc. (Nasdaq: SKYE) announced on April 15, 2025, new preclinical data for its novel CB1 antibody, nimacimab. The study demonstrated over 30% weight loss when nimacimab was combined with tirzepatide in a diet-induced obesity model over 25 days.
The weight loss observed was significantly higher than the 23.5% weight loss seen with tirzepatide alone. Skye Bioscience plans to release further details in late Q3/early Q4 2025.
As of the latest data, Skye Bioscience has a free float of 19,689,100 shares and 32,057,500 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.